永安藥業(002365.SZ)擬與盈美加共同向美深貿易提供總額不超600萬元財務資助
格隆匯 3 月 19日丨永安藥業(002365.SZ)公佈,公司於2021年3月19日召開第五屆董事會第二十一次會議,審議通過《關於為美深(武漢)貿易有限公司提供財務資助的議案》,同意公司與關聯方盈美加科技(武漢)合夥企業(有限合夥)(“盈美加”)共同向美深(武漢)貿易有限公司(“美深貿易”)提供總額不超過600萬元的財務資助,用於其補充臨時的資金流動性需要。此次財務資助公司與關聯股東按比例提供,其中公司以自有資金提供財務資助的總額不超過477.54萬元,盈美加提供財務資助的總額不超過122.46萬元。借款期限自第一筆借款匯入美深貿易指定銀行賬户之日起至2021年12月31日,借款按年利率4.00%收取。具體借款金額以美深貿易實際需要為準,美深貿易可以提前還款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.